Ondansetron Bluefish (Ondansetron Hydrochloride Dihydrate)

Ondansetron works by selectively blocking serotonin (5‑HT3) receptors in the chemoreceptor trigger zone of the brain and on vagal afferent nerves in the gastrointestinal tract. This inhibition prevents serotonin‑mediated activation of the vomiting centre, thereby reducing the sensation of nausea and the act of vomiting.

The specific dose of Ondansetron Bluefish is determined by the prescribing clinician based on the indication, patient weight, renal and hepatic function, and other individual factors. Healthcare professionals follow established clinical guidelines to select an appropriate dosing regimen for each patient.

Ondansetron should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, as safety data are limited. It is excreted in breast milk in small amounts; therefore, a decision to breastfeed while on therapy should be made after consulting a healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Ondansetron belongs to the 5‑HT3 antagonist class, which is generally more effective for acute chemotherapy‑induced nausea than dopamine antagonists such as metoclopramide. It has a lower risk of extrapyramidal side effects but may cause QT prolongation, a consideration not typically associated with older antiemetics.

Store the product at room temperature, below 25 °C, in its original packaging. Protect it from moisture, direct sunlight, and extreme temperatures. Ensure that the container is tightly closed when not in use to maintain product stability.

Ondansetron Bluefish is administered intravenously by a qualified healthcare professional. The injection is given over a short period, usually as a single dose before the emetogenic stimulus (e.g., chemotherapy) or as directed for postoperative use. Administration guidelines are provided in the product labeling.

Serious risks include cardiac arrhythmias due to QT interval prolongation, severe allergic reactions such as anaphylaxis, and rare cases of serotonin syndrome when combined with other serotonergic agents. Patients should be monitored for signs of these conditions, especially if they have pre‑existing cardiac disease or are taking interacting medications.

Ondansetron is contraindicated in individuals with known hypersensitivity to ondansetron or any of its excipients. It should also be avoided in patients receiving apomorphine or those with a history of significant QT prolongation unless the benefits outweigh the risks and appropriate monitoring is in place.